Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Enterprise Value: 2010-2021

Historic Enterprise Value for Neurocrine Biosciences (NBIX) over the last 12 years, with Sep 2021 value amounting to $8.3 billion.

  • Neurocrine Biosciences' Enterprise Value rose 3.60% to $8.3 billion in Q3 2021 from the same period last year, while for Sep 2021 it was $5.7 billion, marking a year-over-year increase of 2.07%. This contributed to the annual value of $8.2 billion for FY2020, which is 11.68% down from last year.
  • Latest data reveals that Neurocrine Biosciences reported Enterprise Value of $8.3 billion as of Q3 2021, which was down 0.06% from $8.3 billion recorded in Q2 2021.
  • Neurocrine Biosciences' Enterprise Value's 5-year high stood at $10.5 billion during Q3 2018, with a 5-year trough of $3.5 billion in Q2 2017.
  • Over the past 3 years, Neurocrine Biosciences' median Enterprise Value value was $8.3 billion (recorded in 2021), while the average stood at $8.3 billion.
  • Per our database at Business Quant, Neurocrine Biosciences' Enterprise Value skyrocketed by 136.01% in 2018 and then declined by 27.71% in 2019.
  • Over the past 5 years, Neurocrine Biosciences' Enterprise Value (Quarterly) stood at $6.4 billion in 2017, then fell by 8.28% to $5.8 billion in 2018, then surged by 58.44% to $9.2 billion in 2019, then fell by 11.68% to $8.2 billion in 2020, then climbed by 3.60% to $8.3 billion in 2021.
  • Its Enterprise Value was $8.3 billion in Q3 2021, compared to $8.3 billion in Q2 2021 and $8.3 billion in Q1 2021.